Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kelly Murphy

Physician Assistant Wakefield, RI Physician Assistant

NPI 1154977221 CMS profile 10441565

1 High St, Wakefield, RI 02879

Open in the dashboard

General payments

$622

15 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Murphy of Wakefield, RI is reported in the CMS Open Payments database as having received $622 across 15 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $329 5
2024 General $75 3
2023 General $121 3
2022 General $45 2
2021 General $53 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Murphy
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kelly Murphy were reported at $329. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kelly Murphy Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $53 $132 $37–$438 $132
2022 $45 $155 $48–$522 $149
2023 $121 $167 $52–$557 $160
2024 $75 $178 $55–$600 $164
2025 $329 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Bioventus LLC $288 6 payments
  2. Smith+Nephew, Inc. $159 2 payments
  3. Ferring Pharmaceuticals Inc. $70 4 payments
  4. Acera Surgical, Inc. $58 2 payments
  5. Pacira Pharmaceuticals Incorporated $47 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $622 15 payments
Products named General payments · program years 2021–2025
  1. EXOGEN ULTRASOUND BONE HEALING SYSTEM $171 2 payments
  2. PICO 7 $96 1 payment
  3. Durolane $78 3 payments
  4. EUFLEXXA $70 4 payments
  5. PICO $64 1 payment
  6. RENASYS Touch $64 1 payment
  7. Restrata Wound Matrix $58 2 payments
  8. Iovera $47 1 payment
  9. Zilretta $47 1 payment
  10. Exparel $47 1 payment
  11. Other $39 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

856

Median for Physician Assistant: 241

Drug cost

$5,059

Median for Physician Assistant: $4,110

Branded share of claims

10%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 90 $1,053
Oxycodone Hcl Generic 153 $764
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 86 $693
Meloxicam Generic 170 $574
Gabapentin Generic 75 $461
Ibuprofen Generic 34 $455
Cyclobenzaprine Hcl Generic 35 $288
Methylprednisolone Generic 30 $260
Tramadol Hcl Generic 69 $193
Tranexamic Acid Generic 19 $114

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$89,938

Of which drugs: $16,259

Medicare patients

342

Average age 76

Services billed

4,715

207 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 33%
Diabetes 24%
Depression 23%
Osteoporosis 19%
Atrial fibrillation 18%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 27 116 $10,952
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 131 1,166 $827
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 131 1,163 $96

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Rhode Island

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record